Khon Kaen University
Phu Wiang, Changwat Khon Kaen, 40002, Thailand
Location status: Recruiting
NCT Number: NCT05321992
Liver cancer, specifically cholangiocarcinoma (CCA), is very common in different areas in Thailand. Many factors make this cancer more common, such as liver fluke infection, older age, eating raw fish, family history of cancer, alcohol intake, taking certain medicines (praziquantel), low intake of fresh vegetable, and low education. In 2015, researchers from Khon Kaen University developed the Community-based Health Education and Communication (CHEC) program to prevent liver cancer caused by liver flukes in communities of the Khon Kaen province, Thailand.
The main aim of this 5-year research study is to enhance the CHEC program to prevent liver cancer, and test if it is effective in improving the knowledge and behaviours of community residents regarding how to prevent liver cancer. This study will take place in Khon Kaen, Thailand. Other aims are to:
1. Increase understanding in the community that make it difficult to prevent liver cancer, as well as community characteristics that can help prevent liver cancer; 2. Incorporate the program we develop in healthcare to prevent liver cancer in Thailand.
Interested in participating?
Request Info20 year and older
All sexes
Interventional
Not applicable
Phu Wiang, Changwat Khon Kaen, 40002, Thailand
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
Time frame: 12 months
Mean difference in the self-reported frequency of intake of raw fish in the intervention group compared to the control group. Self reported, pre- and post- intervention.
Time frame: 12 months
Mean difference in the self-reported frequency of intake of fruits and vegetables in the intervention group compared to the control group. Self reported, pre- and post- intervention.
Time frame: 12 months
Difference in the proportion of smoking habits in the intervention group compared to the control group. Self reported, pre- and post- intervention.
Time frame: 12 months
Mean difference in the intake of alcoholic beverages in the intervention group compared to the control group. Self reported, pre- and post- intervention.
Time frame: 12 months
Difference in the proportion of use of the medication praziquantel (prescribed or self-medicated) in the intervention group compared to the control group. Self reported, pre- and post- intervention.
Time frame: 12 months
Difference in the proportion of positive stool test of concentration of O. viverrini, pre- and post-intervention.
Time frame: 12 months
Difference in the mean concentration of O. viverrini in the stool test, pre- and post-intervention.
Time frame: 12 months
Mean difference in the stages of change for risk behaviours in the intervention group compared to the control group. Self reported, pre- and post- intervention.
Time frame: 12 months
Mean difference in knowledge score about in knowledge of preventative measures against CCA in the intervention group compared to the control group. Measured in questions included in the community survey.
Time frame: 12 months
Cardiobolic measure linked to developing cancer. Change in the mean body mass index calculated from height and weight (self-reported).
Time frame: 12 months
Cardiobolic measure linked to developing cancer. Change in the mean waist circumference (measured with measuring tape)
Time frame: 12 months
Cardiobolic measure linked to developing cancer. Change in the mean measured blood pressure (automated, validated device)
Time frame: 12 months
Mean difference in health literacy knowledge score in the intervention group compared to the control group. Self reported, pre- and post- intervention
Time frame: 12 months
Mean difference in quality of life in the intervention group compared to the control group. Self reported, pre- and post- intervention. Using the EuroQol-5 dimension-5 level (EQ-5D-5L) tool
Contact information is provided by the study sponsor or research team.
McMaster University
Other
Acronym: eCHEC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01915225
Adenocarcinoma, Bile Duct Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT06910670
Adenocarcinoma, Blood Protein Disorders
St Louis, Missouri, United States
View Trial DetailsNCT06340646
Adenocarcinoma, Blood Protein Disorders
St Louis, Missouri, United States
View Trial DetailsNCT05874414
Adenocarcinoma, Bile Duct Diseases
Los Angeles, California, United States
View Trial Details